Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CEL | P19835 | 1/20 | 0.33 |
| ▸ | PPM1D | O15297 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5953581 | 0.89 | BCHE (0.36) | ACHEHTR2CHTR2AHTR2BBCHE | |
| SCHEMBL5953916 | 0.82 | HTR2C (0.34) | ACHEHTR2CHTR2AHTR2BBCHE | |
| SCHEMBL5954156 | 0.80 | GABRA1 (0.39) | HTR2CHTR2AHTR2BKMT2A | |
| SCHEMBL5953662 | 0.77 | HTR1A (0.38) | ACHECEL | |
| SCHEMBL5953670 | 0.75 | HTR2A (0.33) | HTR2CHTR2AHTR2B | |
| SCHEMBL3071175 | 0.71 | ACHE (0.40) | ACHEKMT2AALDH1A1RAB9A | |
| SCHEMBL16191244 | 0.71 | KMT2A (0.47) | BCHEKMT2ACELPPM1DALDH1A1 | |
| SCHEMBL17748782 | 0.69 | CEL (0.42) | BCHECELPPM1DALDH1A1RAB9A | |
| SCHEMBL5954155 | 0.68 | ADRA2A (0.33) | ACHEBCHE | |
| SCHEMBL2385859 | 0.68 | ACHE (0.37) | ACHEKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052620-A1 | Preparation of substituted indenes | BASELL POLYOLEFINE GMBH (DE) | 2006-03-09 | — | — | US | disclosed |
| EP-1492749-A1 | PREPARATION OF SUBSTITUTED INDENES | Basell Polyolefine GmbH (DE) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003084904-A1 | PREPARATION OF SUBSTITUTED INDENES | BASELL POLYOLEFINE GMBH (DE) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052620-A1 | Preparation of substituted indenes | INTS9, CYP1A2, INF2 | ACHE 906/4885HTR2C 3399/4885HTR2A 3428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.